You are here

P&T News

May 26

Finger of suspicion points to Ocrevus, but Tysabri may be the real culprit
“Immutable” changes are on the way, regardless of government policies
Causes include growing population of older adults
First biosimilar erythropoiesis-stimulating agent backed by an FDA panel

May 25

Proposed legislation trims $119 billion from federal deficit
Potentially harmful bacteria acquire antibiotic-resistance genes
Company plans FDA submission by mid-year

May 24

STAT article lists eight ways proposed cuts might affect public health
Approval marks major step in precision medicine
Two-year study shows 2.8% improvement in disease-free survival versus placebo

May 23

Wholesale acquisition cost is $39,000 per year
California takes steps to reduce overly aggressive care
Centers postpone operations, delay chemotherapy

Pages